Vivani Medical Completes $4.5M Capital Raise at $1.48 Per Share

2026-02-06 08:08:42

Abstract generation in progress

Vivani Medical, Inc. (VANI), a clinical-stage biopharmaceutical company focused on obesity and metabolic disease therapeutics, has successfully secured $4.5 million through a combination of registered direct offering and private placement. The company issued 1.69 million shares of common stock through a registered direct offering at $1.48 per share, while Chairman Gregg Williams participated in a concurrent private placement of an additional 1.35 million shares at the same price point. ThinkEquity served as the sole placement agent for this equity offering.

Product Pipeline: Key Words on Clinical Development Strategy

Vivani’s portfolio demonstrates a comprehensive approach to addressing obesity and related metabolic conditions across multiple development stages. The company’s preclinical candidates include NPM-139 and NPM-133, both semaglutide-based formulations targeting obesity/weight management and type 2 diabetes respectively. Additionally, OKV-119, an Exenatide-based therapeutic, targets canine and feline obesity in the veterinary space. Most significantly, NPM-115 Exenatide has advanced to the clinical stage for obesity and weight management applications. The company has signaled its intention to initiate clinical development of NPM-139 in 2026, representing a major inflection point for the biopharmaceutical venture.

Strategic Capital Deployment and Market Position

The net proceeds from the offering will be allocated toward accelerating research and clinical development of Vivani’s product candidates, while also supporting operational requirements and general corporate activities. This capital infusion positions the company to advance its clinical pipeline as it pursues FDA-regulated pathways in the high-demand obesity and metabolic disease markets. Over the past year, VANI shares have traded within a $0.90 to $1.92 range, reflecting the typical volatility of early-stage biotech securities as investors assess clinical progress and commercial potential.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.